Revolution Medicines, Inc. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Revolution Medicines, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-06-30 was $8.47M, a 82.45% increase year-over-year.
- Revolution Medicines, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-06-30 was $4.64M, a 46.78% increase year-over-year.
- Revolution Medicines, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2024-06-30 was $3.16M, a 50.02% increase year-over-year.
- Revolution Medicines, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2023-06-30 was $2.11M, a 70.22% increase year-over-year.
- Revolution Medicines, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $8.04M, a 59.79% increase from fiscal 2024.
- Revolution Medicines, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $5.03M, a 51.61% increase from fiscal 2023.
- Revolution Medicines, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $3.32M, a 77.95% increase from fiscal 2022.
- Revolution Medicines, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $1.86M, a 0.59% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-06-30 | $8.47M 10-Q · filed 2026-08-05 | |
| 2025-12-31 | $8.04M 10-K · filed 2026-02-25 | |
| 2025-06-30 | $4.64M 10-Q · filed 2026-08-05 | |
| 2024-12-31 | $5.03M 10-K · filed 2026-02-25 | |
| 2024-06-30 | $3.16M 10-Q · filed 2025-11-05 | |
| 2023-12-31 | $3.32M 10-K · filed 2026-02-25 | |
| 2023-06-30 | $2.11M 10-Q · filed 2024-11-06 | |
| 2022-12-31 | $1.86M 10-K · filed 2025-02-26 | |
| 2022-06-30 | $1.24M 10-Q · filed 2023-11-06 | |
| 2021-12-31 | $1.88M 10-K · filed 2024-02-26 | |
| 2021-06-30 | $1.18M 10-Q · filed 2022-11-07 | |
| 2020-12-31 | $832.00K 10-K · filed 2023-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |